As part of our commitment to constantly improving growth factor quality and availability, we will introduce a modest price increase on January 1st 2024.
Dear Valued Customer,
We deeply appreciate your trust in Qkine animal-free growth factors and cytokines to advance your scientific endeavors in the stem cell sector. Your satisfaction is our utmost priority, and we continue to be committed to delivering exceptional quality and support.
We will implement a modest price adjustment effective January 1st 2024 to support our continuous pursuit of excellence. Rest assured, this increase ensures we can sustain the high level of service and innovation you expect from us whilst remaining competitively priced.
Over the past year, as part of our commitment to raising industry standards and saving you time and resources, we have:
- Enhanced our already rigorous lot-specific quality control measures, including densitometry analysis, sterility testing, mycoplasma testing, and application-specific testing to ensure the reliability and reproducibility of our proteins.
- Expanded our product range and tackled stem cell challenges with collaborators across fields that include complex 3D stem cell culture platforms, optimized stem cell maintenance media and cellular agriculture.
- Implemented process changes as part of our long-term commitment to sustainable manufacturing and scientific innovation.
- Launched our bioactivity guarantee, which assures all Qkine proteins exhibit equivalent or superior bioactivity compared to alternatives, facilitating cost-effective scaling for your research.
Our commitment to enhancing processes and expanding our product range remains unwavering. With Qkine, you can always trust our growth factor quality, and our scientific integrity.
Should you have any inquiries or wish to request a quote ahead of the price adjustment, please do not hesitate to contact us at customerservice@qkine.com. We are here to support your scientific journey every step of the way.
Thank you for being a valued part of the Qkine community.
Best regards,
Dr Catherine Elton
CEO, Qkine